No evidence of presence of parvovirus 4 in a Swedish cohort of severely immunocompromised children and adults.
The recently discovered human parvovirus 4 (PARV4) has been associated with seropositivity for human immunodeficiency virus, hepatitis B virus and hepatitis C virus. High prevalence is seen especially in intravenous drug users. The virus has been detected in blood products and persons who have been repeatedly transfused have shown to be a risk-group. Furthermore, reports from different parts of the world suggesting a prevalence ranging from zero to one third of the healthy population and the virus is thought to cause a latent or persistent infection. We investigated the presence of PARV4 DNA and parvovirus B19 (B19) DNA in serum from 231 severely immunocompromised cancer patients that have been exposed for blood products. Compared to B19, which was found in 3.9% of the patients, we found no evidence of PARV4. Our results may indicate a very low prevalence of the virus in Sweden, and it would be useful to measure the real PARV4 exposure of the healthy population as well as individuals with known risk factors by serology.
Department of Medicine, Solna, Infectious Disease Unit, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Thomas
T
Tolfvenstam
Oscar
O
Norbeck
Lars
L
Ohrmalm
D000293:Adolescent; D000328:Adult; D002648:Child; D004279:DNA, Viral / Q000235:genetics; D006801:Humans; D016867:Immunocompromised Host; D010322:Parvoviridae Infections / Q000175:diagnosis*; D017992:Parvovirus / Q000235:genetics / Q000472:pathogenicity*; D055815:Young Adult
D004279:DNA, Viral